Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation

Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation

Mohamed Hamouda,1 Mohamed Farghaly,2 Sara Al Dallal2,3 1Value Access & HEOR, GSK, Dubai, United Arab Emirates; 2Health Insurance Section, Dubai Health Authority, Dubai, United Arab Emirates; 3Emirates Health Economics Society, Dubai, United Arab EmiratesCorrespondence: Mohamed Hamouda, Value Acc...

Full description

Bibliographic Details
Main Authors:	Hamouda M, Farghaly M, Al Dallal S
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-07-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	asthma asthma maintenance therapy budget impact analysis triple therapy united arab emirates
Online Access:	https://www.dovepress.com/budget-impact-analysis-of-single-inhaler-fluticasone-furoateumeclidini-peer-reviewed-fulltext-article-CEOR

Similar Items

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
by: Bogart M, et al.
Published: (2023-12-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)

Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study
by: Hozawa S, et al.
Published: (2021-07-01)

COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
by: Hanania NA, et al.
Published: (2023-03-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01)

Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
by: Panettieri Jr RA, et al.
Published: (2022-09-01)

Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States
by: Bogart M, et al.
Published: (2024-01-01)

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
by: George Bardsley, et al.
Published: (2018-07-01)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
by: Akira Umeda, et al.
Published: (2023-04-01)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
by: Ryo Atsuta, et al.
Published: (2018-10-01)

Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial
by: Oliver Amanda, et al.
Published: (2012-06-01)

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
by: Peter Daley-Yates, et al.
Published: (2022-09-01)

Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma
by: Akira Umeda, et al.
Published: (2019-01-01)

Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review
by: A. A. Viesel, et al.
Published: (2022-01-01)

Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study
by: Daniel Dedman, et al.
Published: (2019-04-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
by: Sandeep Bansal, et al.
Published: (2021-05-01)

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
by: Jacques Loretta, et al.
Published: (2011-10-01)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
by: Sally Worsley, et al.
Published: (2019-11-01)

Assessment of Novel Inhaler Technique Reminder Labels in Image Format on the Correct Demonstration of Inhaler Technique Skills in Asthma: A Single-Blinded Randomized Controlled Trial
by: Iman Basheti, et al.
Published: (2021-02-01)

Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy
by: Bogart M, et al.
Published: (2024-02-01)

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial
by: Beeh KM, et al.
Published: (2024-01-01)

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects
by: Mario Malerba, et al.
Published: (2018-03-01)

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma
by: Serafeim-Chrysovalantis Kotoulas, et al.
Published: (2023-07-01)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
by: Woodcock Ashley, et al.
Published: (2011-12-01)

Peculiarities of Mild Asthma in Russia: the Results of SYGMA2 Study
by: Zaurbek R. Aisanov, et al.
Published: (2021-04-01)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
by: Afisi S. Ismaila, et al.
Published: (2023-09-01)

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience
by: Timothy E. Albertson, et al.
Published: (2016-02-01)

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study
by: Henrik Watz, et al.
Published: (2020-04-01)

Bronchial Asthma: Current Trends in Treatment
by: Palova R, et al.
Published: (2020-04-01)

Characterizing Real-World Use Of Tiotropium In Asthma In The USA
by: Averell CM, et al.
Published: (2019-10-01)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
by: François Maltais, et al.
Published: (2019-10-01)

A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
by: Philippe Bareille, et al.
Published: (2020-02-01)

The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice
by: V. V. Naumova, et al.
Published: (2022-04-01)

Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
by: Afisi S. Ismaila, et al.
Published: (2024-04-01)

Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma–COPD overlap syndrome consulting for routine care
by: Ding B, et al.
Published: (2018-03-01)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
by: Bernstein David I, et al.
Published: (2011-12-01)

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
by: Courtney Crim, et al.
Published: (2020-05-01)

Effects of inhaled beclomethasone dipropionate/formoterol fumarate/glycopyrronium on diaphragmatic workload and lung function in uncontrolled asthma: a case report
by: Antonio Maiorano, et al.
Published: (2024-03-01)

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
by: Caramori G, et al.
Published: (2014-02-01)